Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Biomaterials. 2018 May 26;176:71–83. doi: 10.1016/j.biomaterials.2018.05.041

Fig. 8. The THR peptide competes with the human transferrin binding to AAV8.

Fig. 8

Diluted HSA (1:100 and 1:100,000 of physiological concentration), peptide control (1:100 and 1:100,000 dilution), THR (1:100 and 1:100,000 dilution), and DPBS control were used to block the AAV8 capsid on Huh7 cells in vitro. Then, the human transferrin (1:100 of physiological concentration) was added to the mixture separately, the transferrin antibody was used for pull down, and the AAV8 gene copy number was measured by qPCR. All of the data were shown as the means of the triplicate experiments and SD. Asterisks indicate the statistical significance when compared to the DPBS group (**p < 0.01, ****p < 0.001). The “ns” indicates no significant difference (p> 0.05).